News & Events

Jan 08, 2020

ViaCyte to Present at Biotech Showcase 2020 in San Francisco

Read More

Dec 09, 2019

CIRM Alpha Stem Cell Clinic Symposium

Read More

Dec 09, 2019

Rachmiel Levine Symposium

Read More

Dec 09, 2019

CHI’s Cell Therapy Analytics & Manfacturing

Read More

Dec 09, 2019

Biotech Showcase

Read More

Nov 04, 2019

ViaCyte to Present at ISSCR International Symposium: Stem Cell Biology to New Therapies

Read More

Oct 03, 2019

ViaCyte to Present Preliminary PEC-Direct Clinical Data at Cell & Gene Meeting on the Mesa

Read More

Sep 17, 2019

CRISPR Therapeutics and ViaCyte Present Positive In Vitro Data Towards a Potential Immune-Evasive Cell Replacement Therapy for Diabetes at EASD 2019

Read More

Jul 24, 2019

ViaCyte to Expand Board of Directors with Two New Appointments

Read More

Jun 27, 2019

ViaCyte Appoints Sandra E. Poole to Board of Directors

Read More

Jan 29, 2019

ViaCyte Announces New Board Members

Read More

Jan 21, 2019

Center for Beta Cell Therapy in Diabetes and ViaCyte Announce Start of European Clinical Trial of Human Stem Cell-derived Implants in Type 1 Diabetes Patients

Read More

Jan 04, 2019

ViaCyte Provides Update on Patent Portfolio in Stem Cell-Derived Cell Replacement Therapies for Type 1 Diabetes and Other Indications

Read More

Nov 28, 2018

ViaCyte Secures $80 Million Financing to Advance Functional Cures for Insulin-Requiring Diabetes

Read More

Sep 27, 2018

ViaCyte to Present at Investor, Partnering, and Scientific Conferences in October

Read More

Sep 25, 2018

Gore Strengthens Collaborative Relationship with ViaCyte by Investing Additional $10 Million

Read More

Sep 17, 2018

CRISPR Therapeutics and ViaCyte Announce Strategic Collaboration to Develop Gene-Edited Stem Cell-Derived Therapy for Diabetes

Read More

Jun 23, 2018

Two-year Data from ViaCyte’s STEP ONE Clinical Trial Presented at ADA 2018

Read More

May 25, 2018

ViaCyte to Present at the American Diabetes Association’s 78th Scientific Sessions

Read More

Apr 17, 2018

ViaCyte Awarded NIH SBIR Grant to Support In Vitro Development of Stem Cell-Derived Functional Human Pancreatic Beta Cells

Read More

Apr 17, 2018

ViaCyte Substantially Expands Patent Portfolio in Stem Cell-Derived Cell Replacement Therapies for Type 1 Diabetes and Other Indications

Read More

Apr 12, 2018

ViaCyte to Present at Alliance for Regenerative Medicine’s 6th Annual Cell & Gene Therapy Investor Day in New York City

Read More

Jan 19, 2018

ViaCyte to Present at Three Upcoming Healthcare Events

Read More

Jan 05, 2018

ViaCyte Announces First Patients Implanted in Cohort 2 with Potentially Efficacious Dose of PEC-Direct Islet Cell Replacement Therapy

Read More

Dec 15, 2017

CIRM Grants ViaCyte $1.4M to Create Immune-Evasive Pluripotent Stem Cell Lines

Read More

Dec 06, 2017

ViaCyte Selected as a Winner of CONNECT’s 30th Annual Most Innovative New Product Awards

Read More

Oct 04, 2017

ViaCyte to Present at Upcoming Investor and Partnering Events in October

Read More

Sep 28, 2017

ViaCyte Awarded New CIRM Grant to Support Clinical Trial of PEC-Direct Product Candidate for High-Risk Type 1 Diabetes

Read More

Sep 21, 2017

ViaCyte Selected as a Finalist for CONNECT’s 30th Annual Most Innovative New Product Awards

Read More

Sep 07, 2017

ViaCyte to Present at Upcoming Scientific Meetings on Diabetes Research

Read More

Aug 01, 2017

ViaCyte Announces First Patients Implanted with PEC-Direct Islet Cell Replacement Therapy in International Clinical Trial

Read More

Jun 15, 2017

ViaCyte Presents at the ISSCR 2017 Annual Meeting in Boston

Read More

May 22, 2017

ViaCyte Receives IND Allowance from FDA and Clearance from Health Canada to Commence International Clinical Trial of PEC-Direct Cell Therapy for High-Risk Type 1 Diabetes

Read More

May 22, 2017

ViaCyte Announces $10 Million in Financing

Read More

May 22, 2017

JDRF and ViaCyte Announce Support for Development of PEC-Direct Cell Replacement Therapy for Type 1 Diabetes

Read More

Apr 24, 2017

ViaCyte to Present at ARM’s 5th Annual Cell & Gene Therapy Investor Day in Boston

Read More

Mar 29, 2017

ViaCyte and W. L. Gore & Associates Announce Collaborative Research Agreement to Develop Novel Implantable Delivery Technologies for Cell Therapies

Read More

Feb 23, 2017

Beyond Type 1 Provides Grant to ViaCyte to Support Research and Development of Cell Replacement Therapies for Type 1 Diabetes

Read More

Feb 21, 2017

ViaCyte to Present at Four Upcoming Healthcare Events

Read More

Jan 04, 2017

Twenty-two New Patents Are Added To ViaCyte’s Intellectual Property Portfolio

Read More

Nov 04, 2016

ViaCyte to Present at Healthcare Events in November

Read More

Oct 11, 2016

ViaCyte to Present at Healthcare Events in October

Read More

Oct 04, 2016

ViaCyte to Provide a Corporate Update at 2016 Cell and Gene Meeting on the Mesa

Read More

Sep 09, 2016

ViaCyte to Speak on Diabetes Panel at BioPharm America 2016

Read More

Aug 12, 2016

ViaCyte to Present at Rejuvenation Biology 2016

Read More

Jul 21, 2016

ViaCyte Awarded New CIRM Grant to Develop PEC-Direct for High-Risk Type 1 Diabetes

Read More

Jun 22, 2016

ViaCyte to Present at ISSCR 2016 Annual Meeting

Read More

Apr 20, 2016

ViaCyte to Present at Healthcare Events in April and May

Read More

Mar 14, 2016

ViaCyte to Present at Upcoming Healthcare Events

Read More

Mar 01, 2016

ViaCyte to Present at JDRF TypeOneNation Summit Meetings in Washington DC and Los Angeles

Read More

Feb 17, 2016

ViaCyte to Present at Upcoming Healthcare Events

Read More

Feb 03, 2016

ViaCyte Acquires Rights to BetaLogics Assets, Expanding and Extending Industry-Leading Portfolio for Stem Cell-Derived Approaches to Type 1 Diabetes

Read More

Jan 06, 2016

ViaCyte to Present at Biotech Showcase 2016 in San Francisco

Read More

Nov 17, 2015

ViaCyte to Present at IDF World Diabetes Congress 2015

Read More

Nov 16, 2015

ViaCyte Licenses Cell Differentiation Technology to Takara Bio Inc.

Read More

Oct 15, 2015

ViaCyte to Present at 14th Annual BIO Investor Forum

Read More

Sep 24, 2015

ViaCyte to Present at Upcoming Healthcare Events

Read More

Sep 10, 2015

ViaCyte Announces the Publication of a Report on Macroencapsulated Stem Cell-Derived Insulin-Producing Cells and the Issuance of Three Patents

Read More

Jul 29, 2015

ViaCyte Announces Second Clinical Trial Site at University of Alberta

Read More

Jun 16, 2015

ViaCyte to Present Plenary Lecture at ISSCR 2015 Annual Meeting

Read More

May 14, 2015

ViaCyte to Present at London Regenerative Medicine Network and The World Stem Cells and Regenerative Medicine Congress 2015

Read More

May 11, 2015

ViaCyte to Present at Cavendish Global Health Impact Forum

Read More

Apr 23, 2015

ViaCyte to Present at GTCbio 2015 Diabetes Summit

Read More

Mar 17, 2015

ViaCyte to Present at ARM’s Third Annual Regen Med Investor Day

Read More

Mar 03, 2015

ViaCyte to Present at JDRF TypeOneNation Research Summit

Read More

Feb 26, 2015

ViaCyte to Present at 35th Annual Cowen and Company Health Care Conference

Read More

Feb 23, 2015

ViaCyte to Present at Two San Diego Events: Biocom’s Global Life Science Partnering Conference and UCSD Diabetes Public Forum

Read More

Jan 12, 2015

JDRF Honors Current and Former ViaCyte Team with Top Scientific Excellence Award

Read More

Jan 08, 2015

ViaCyte Receives Clearance from Health Canada for Diabetes Clinical Trial

Read More

Dec 22, 2014

ViaCyte to Present at Biotech Showcase in San Francisco

Read More

Dec 18, 2014

Study Further Validates Cell Therapy Approach to Reverse Type 1 Diabetes

Read More

Nov 20, 2014

ViaCyte to Present at 26th Annual Piper Jaffray Healthcare Conference

Read More

Nov 06, 2014

ViaCyte Receives U.S. Patent Claiming Alternative Methods to Manufacture Pancreatic Progenitor Cells In Vitro

Read More

Oct 29, 2014

ViaCyte’s VC-01™ Investigational Stem Cell-Derived Islet Replacement Therapy Successfully Implanted into First Patient

Read More

Oct 06, 2014

ViaCyte, Inc. to Present at Upcoming Stem Cell Meeting on the Mesa Conference

Read More

Sep 10, 2014

ViaCyte, Inc. Awarded $16.6 Million Accelerated Development Pathway Grant from CIRM to Expand Clinical Development of its VC-01™ Diabetes Therapy Candidate

Read More

Aug 21, 2014

ViaCyte, Inc. Announces Signing of Rights Agreement with Janssen Research & Development LLC.

Read More

Aug 19, 2014

ViaCyte, Inc. Announces FDA Acceptance of IND to Commence Clinical Trial of VC-01™ Candidate Cell Replacement Therapy for Type 1 Diabetes

Read More

Aug 08, 2014

ViaCyte, Inc. Raises $5.4 Million in a Private Financing to Support Clinical Development of its Cell Therapy Product VC-01™ for Insulin-Dependent Diabetes

Read More

Jul 17, 2014

ViaCyte Files Investigational New Drug Application and Device Master File with FDA for Novel Cell Replacement Therapy Product Candidate Designed to Treat Patients with Type 1 Diabetes

Read More

Jul 08, 2014

ViaCyte Achieves Significant Milestone with ISO 13485:2003 Certification for its Encaptra Drug Delivery System

Read More

May 29, 2014

ViaCyte and Asterias Biotherapeutics Settle Patent Dispute

Read More

Feb 06, 2014

JDRF to Provide Additional Support for Upcoming Clinical Trial of ViaCyte’s Encapsulated Cell Therapy for Type 1 Diabetes

Read More

Dec 19, 2013

ViaCyte Appoints Mark Foletta, former CFO of Amylin, to its Board of Directors

Read More

Dec 02, 2013

ViaCyte to Present at the 25th Piper Jaffray Healthcare Conference

Read More

Oct 29, 2013

ViaCyte Granted Over 20 Patents in 2013 Further Establishing the Company as a Leader in the Field of Regenerative Medicine

Read More

Oct 16, 2013

ViaCyte to Present at the JDRF 8th Annual T1D Global Path to a Cure Symposium

Read More

Oct 10, 2013

Viacyte to Present Update On VC-01™ Combination Product Development at 2013 Stem Cell Meeting on The Mesa

Read More

Jul 10, 2013

ViaCyte, Inc. raises $10.6 Million in a Private Financing to Support Clinical Development of its Cell Therapy Product for Insulin Dependent Diabetes

Read More

Jul 03, 2013

Viacyte Inc. selected as one of 2013’s “Cool Companies”

Read More

Feb 13, 2013

JDRF and California Institute for Regenerative Medicine Increase Funding of ViaCyte

Read More

Jan 31, 2013

ViaCyte’s Role as a Leading Cell Therapy Company Bolstered with the Issuance of 20 Patents in 2012

Read More

Oct 29, 2012

ViaCyte Appoints Steve Altman to its Board of Directors

Read More

Oct 26, 2012

ViaCyte Receives $10.1 Million Strategic Partnership Award from CIRM to Continue Development of Diabetes Therapy

Read More

Jun 25, 2012

ViaCyte Appoints Dr. Paul Laikind Chief Executive Officer

Read More

Mar 12, 2012

ViaCyte Licenses Technologies to Nestlé Institute of Health Sciences

Read More

Aug 09, 2011

ViaCyte Announces Executive Management Changes

Read More

Apr 13, 2011

Cellular Dynamics Licenses Technology from ViaCyte

Read More

May 05, 2010

ViaCyte, Inc., Receives Three Additional U.S. Patents, Supporting its Development of a Stem Cell Derived Treatment for Diabetes

Read More

May 05, 2010

Novocell Becomes ViaCyte, Inc, as it Accelerates Pre-clinical Development of a Stem Cell Derived Treatment for Diabetes

Read More